Title	CpG-2722 寡脫氧核苷酸及其免疫組成物
	CpG-2722 oligodeoxynucleotide and its immune
	composition
Key summary	本案所開發的 CpG-2722 寡脫氧核苷酸,在人與不同
	的物種中均有良好的免疫調節力。醫學方面的應用包
	括,作為細胞(如樹突狀細胞等)冶療的免疫調節劑,
	癌症冶療葯物的合併使用劑,以及人或動物用的疫苗
	佐劑。
	The CpG-2722 oligodeoxynucleotide developed in this
	study has good immune stimulatory activity in humans
	and different species. Medical applications of this CpG-
	2722 include used as immunomodulators for cell (such
	as dendritic cells) therapy, combinational use with other
	drugs for cancer therapy, and used as vaccine adjuvants.
Targeted indication	Adoptive cell therapy, Cancer Immunotherapy, Vaccine
	adjuvant for human and animals.
Status	Pre-clinical study with animal model
Key features	• CpG-2722 has good immunostimulatory activity in
	different species.
	• CpG-2722 can promote the expression of various
	cytokines and increase the number of dendritic
	cells, M1 macrophages, and CD8 T cells in tumors.
	 Both CpG-2722 can inhibit tumor growth when used
	alone.
	 When CpG-2722 and anti-PD-1 are used in
	combination, their anti-tumor activity is further
	enhanced.
Market	Adoptive cell therapy, Cancer immunotherapy, Vaccine
	adjuvant for human and animals.
Mode of Action	CpG-ODN triggers innate immune responses including
	cytokine production and the uptake and presentation of
	tumor antigen in dendritic cells and other innate immune
	cells. These adjuvant effects, particularly the production
	of IL-12 and type I IFNs, facilitate a Th1 response of T
	cells and expansion of tumor-specific T cells for tumor
	killing.
Experimental	• CpG-2722 has potent activity in inducing expression
results	of various cytokines in immune cells.

	• In head and neck cancer animal models, both CpG-
	2722 increases the expression of various cytokines
	such as II -12 IFN- β and IFN- γ and increase the
	number of dendritic cells M1 macronhages and
	CD8 T cells in tumors
	 In head and neck cancer animal models, both CnG
	2722 and anti PD 1 antihody can inhibit tumor
	2722 and anti-FD-1 antibody can initial tumor
	growth when used alone, and when these two are
	used in combination, then anti-tumor activity is
	• A CpG-1018 has been used as an adjuvant in a FDA
	approved Hepatitis B vaccine. In general CpG-
	oligodeoxynucleotides (CpG-ODNs) have a safety
	profile for using in human bodies. Nevertheless,
	because the CpG-2722 has different nucleotide
	sequences with other CpG-ODNs, its toxicity and
	safety to humans needs further investigated.
	• CpG-ODNs can be synthesized automatically with
	machine.
Intellectual	1.Taiwan patent I653240 (approved in 2020)
property	2. US patent US 10246715 (approved in 2020)
	3. Mainland China patent application pending
	(Publication No: CN109593765)
	4. Hong Kong patent application pending
Selected	1. Yeh DW, Lai CY, Liu YL, Lu CH, Tseng PH, Yuh CH,
Publication	Yu GY, Liu SJ, Leng CH, Chuang TH (2017). CpG-
	oligodeoxynucleotides developed for grouper toll-like
	human TL POs mediated immune responses. Sei Pen
	2017 Dec 11:7(1):17297.
	2. Chuang YC, Tseng JC, Yang JX, Liu YL, Yeh DW, Lai
	CY, YUGY, HSULC, Huang CM, Chuang TH. (2020) Toll Like Recentor 21 of Chicken and Duck Recognize
	a Broad Array of Immunostimulatory CnG-
	oligodeoxynucleotide Seguences Vaccines (Basel).
	8(4):639.
	3. Chuang YC, Tseng JC, Huang LR, Huang CM, Huang
	CF, Chuang TH. (2020) Adjuvant Effect of Toll-Like
	Recentor 9 Activation on Cancer Immunotherany

	Using Checkpoint Blockade. Front Immunol. 11:1075.
	 4. Tseng JC, Yang JX, Liu YL, Su YW, Lee AY, Chen YW, Liu KJ, Luo Y, Hong YR, Chuang TH. (2021) Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide. Cancer Immunol Immunother. 2021 Sep 28. doi: 10.1007/s00262-021-03062-8.
Business	Adoptive cell therapy, Cancer immunotherapy, Vaccine
opportunity	adjuvant for human and animals.